News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Onvista Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Freeport-McMoRan (NYSE:FCX) is in focus as copper prices reach fresh highs, driven by strong demand from electrification and computing, coupled with constrained supply. The company, a major copper producer, benefits significantly from these rising prices, which reinforce its strategic position in the metals and …
Wall Street Zen upgraded Neumora Therapeutics (NASDAQ:NMRA) from a "strong sell" to a "sell" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $6.57. NMRA shares recently dropped by 7.5%, opening at $1.60, and the company reported …
Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 loss of $0.23 per share, exceeding analyst expectations by $0.01. Despite beating estimates, the stock fell by $0.13 to $1.60 and remains significantly below its 12-month high. Institutional investors own 47.65% of the company, and analysts have a …
Neumora Therapeutics (NMRA) reported a diluted loss per share of $0.23 for Q2 2026, representing a net loss of $43.1 million. The clinical-stage biopharmaceutical company narrowed its per-share loss by 30.3% year-over-year compared to Q2 2025. This performance is typical for biopharma companies in …
This article reports on Neumora Therapeutics Inc.'s Form 8K filing for August 14. The filing contains important company information for investors, who should review the full document for complete details. The stock symbol for Neumora Therapeutics Inc. is NMRA, and it experienced a -7.51% …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Freeport-McMoRan (FCX) is back on investor watch after Chief Accounting Officer Ellie L. Mikes sold 4,773 shares on 5 August at US$70.00, trimming …
Freeport-McMoRan's stock appears fully priced despite a strong five-year performance and recent copper discovery news, with its current P/E ratio significantly higher than industry averages. The article suggests the stock is overvalued based on market multiples, and investors' views on its future depend on …
Damora Therapeutics Director Andrew Cheng was granted stock options to purchase 30,350 ordinary shares on August 12, 2026, as revealed in a recent SEC Form 4 filing. The options have an exercise price of $31 per share and will vest in equal monthly installments …
Damora Therapeutics director Andrew Cheng was granted 30,350 stock options on August 12, 2026, with an exercise price of $31.00 per share and an expiration date of August 12, 2036. These options will vest in equal monthly installments through August 12, 2029, contingent on …
Damora Therapeutics (DMRA) has filed a Form 3, an initial statement of beneficial ownership, for Andrew Cheng, identifying him as a new director. This filing officially establishes Cheng as a reporting person with the SEC, though it reports no stock transactions at this time. …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Freeport-McMoRan stock has delivered a strong 118.9% total return over the past five years, yet the current valuation checks and market multiples suggest …
Levi & Korsinsky, LLP has announced a securities class action lawsuit against Freeport-McMoRan Inc. (NYSE:FCX) on behalf of investors who purchased securities between February 15, 2022, and September 24, 2025. The lawsuit alleges that Freeport-McMoRan made false statements and concealed inadequate safety measures at …
Ellie L. Mikes, Chief Accounting Officer at Freeport-McMoRan, sold 4,773 shares for $334,000, reducing her direct equity by 12% and leaving her with 36,000 restricted stock units. This sale, executed at a price higher than the previous day's close, occurred after a 73% stock …
Ellie L. Mikes, Chief Accounting Officer at Freeport-McMoRan, sold 4,773 shares of the company's common stock for approximately $334,000 on August 5, 2026. This transaction reduced her direct equity position by 12%, though she still holds 36,000 restricted stock units. The sale followed a …
Southern Copper (SCCO) is gaining investor attention due to rising copper demand from AI data centers and power grid upgrades, leading to a significant 112% one-year shareholder return. Despite this momentum, a popular narrative suggests the stock is 16.1% overvalued, with a fair value …
RBC Capital has reiterated its Buy rating on Damora Therapeutics (DMRA.US), maintaining a target price of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Freeport-McMoRan (NYSE: FCX) has significantly outperformed the market over the last decade, with an annualized return of 19.07%. An initial investment of $100 in FCX stock 10 years ago would now be worth $568.45. This performance highlights the substantial impact of compounded returns on …
Sharemaestro market context Trend signal active 52 weeks +42.9%Argus has raised its target price for Freeport-McMoRan Inc. (FCX) due to a strong earnings outlook. The report highlights Freeport-McMoRan as a leading international mining company with significant reserves of copper, gold, and molybdenum, based in Phoenix. Full details are available exclusively to Yahoo …
Argus has increased its price target for Freeport-McMoRan (NYSE: FCX) to $78 from $72, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook for the specialty mining and metals company. The article briefly mentions recent news and financial data …
Annex Advisory Services LLC decreased its holdings in Freeport-McMoRan Inc. by 4.6%, selling 36,406 shares, but still retains a significant stake of 756,244 shares valued at $47.56 million. Despite insider selling, institutional investors own over 80% of FCX, and analysts maintain a "Moderate Buy" …
Freeport Indonesia announced that its Gresik unit has temporarily ceased smelting operations to conduct necessary furnace repairs. This update was provided by the company on August 11, 2026, at 09:25 PM EDT. The article is reserved for members of MarketScreener.
Freeport-McMoRan Inc. (FCX) saw its stock fall by 2.33% on Tuesday, closing at $68.87. This underperformance occurred during a generally negative trading session for the stock market, with both the S&P 500 and Dow Jones Industrial Average also declining. The stock's drop ended a …
Sharemaestro market context Trend signal active 52 weeks +81.6% · Next-week setup positive 58.6%Neumora Therapeutics Inc is projected to report an earnings loss of 24 cents per share. This information is provided as an earnings preview.
Southern Copper Corp (SCCO) stock dropped by 3.14% on August 11, primarily due to technical adjustments from its ex-dividend date for both cash and stock dividends. Additional factors contributing to the decline included profit-taking in industrial metals after a copper futures rally, and investor …
Damora Therapeutics, Inc. (DMRA) filed a post-effective amendment to its S-3 registration statement on August 10, 2026. This amendment follows the company's redomestication from Delaware to the Cayman Islands on July 16, 2026, and clarifies that no new securities are being registered. The filing …
Metals Acquisition (ASX:MAC) is attracting investor attention as the market evaluates its mine optimization strategies and copper cash flow potential. Key factors shaping expectations include operating evidence, financial discipline, and execution quality within Australia's evolving market. The article highlights that orebody quality, project returns, …
Damora Therapeutics reported a net loss of $31.2 million for Q2 2026, a significant increase from $3.4 million in the prior year, primarily due to soaring R&D expenses for its CLARITY-101 trial. Despite the widening loss, the company boasts strong liquidity with $540.5 million …
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings, reporting a loss of $0.39 per share, which surpassed analysts' consensus estimate of a $0.45 loss by $0.06. Following the announcement, shares fell 1.3% to $29.54, resulting in a market capitalization of approximately $1.82 …
Damora Therapeutics, Inc. announced its financial results for the second quarter and first six months of 2026, ending June 30th. The company reported a significant increase in net loss for both periods compared to the previous year. For the second quarter, the net loss …
Damora Therapeutics, Inc. Common Stock (DMRA) reported Q2 2026 earnings on August 10, 2026, with an EPS of -$0.39, beating the consensus estimate of -$0.45. The company's earnings are projected to decrease in the next year, from ($2.06) to ($2.14) per share. The article …
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Freeport-McMoRan Inc. (FCX) on behalf of investors who suffered losses due to alleged securities fraud between February 15, 2022, and September 24, 2025. The lawsuit claims Freeport-McMoRan Inc. made false statements and …
Damora Therapeutics (DMRA) has initiated its Phase 1/1b CLARITY-101 trial for DMR-001, a first-in-class antibody targeting mutant calreticulin in myelofibrosis and essential thrombocythemia. This trial launch de-risks execution and provides a clear catalyst with mid-2027 data, though risks remain due to the company's early-stage, …
Search by ticker symbol or company name and select a result to open its chart.